MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Evolution of ataxia in risk persons for spinocerebellar ataxia (SCA)

H. Jacobi, S. Tezenas Dumontcel, T. Klockgether, O. The-Risca-Investigators (Bonn, Germany)

Meeting: 2019 International Congress

Abstract Number: 258

Keywords: Ataxia: Clinical features, Spinocerebellar ataxias(SCA)

Session Information

Date: Monday, September 23, 2019

Session Title: Ataxia

Session Time: 1:45pm-3:15pm

Location: Les Muses, Level 3

Objective: To study the premanifest stage of the most common SCAs. Specifically, we wanted to determine the conversion rate to ataxia in risk persons and to determine the sensitivity of different assessment instruments to detect disease manifestation and progression before onset of ataxia.

Background: Spinocerebellar ataxias (SCAs) are fully penetrant autosomal dominantly inherited progressive ataxia disorders. At risk individuals for SCAs provide a unique research opportunity to prospectively study the premanifest disease phase.

Method: The prospective study of individuals at risk for spinocerebellar ataxia type 1,2,3 and 6 (RISCA) is a multinational, longitudinal observational study.[1] 302 non-ataxic (SARA score <3) adult individuals that descended from a SCA patient (offspring and sibs) were included at 14 European study centres. Anonymous genetic tests were done in all study participants. Follow-up assessments were done in 2-year intervals. Outcome parameters were SARA, INAS, SCAFI and CCFS. In this interim analysis, we included 83 SCA1, 45 SCA3, and 22 SCA6 at risk individuals who had at least one follow-up.

Results: During the observational period of maximally 9.4 years (mean 4.4 ± 2.2), 51% of SCA1, 42% of SCA3, and 13% of SCA6 mutation carriers converted to manifest ataxia. In SCA1 carriers, SARA, INAS, SCAFI and CCFS progression, in SCA3, SARA progression differed from those of non-carriers. None of the parameters significantly changed in non-converters of any genotype.

Conclusion: Our study for the first time determined the conversion rate of SCA mutation carriers to manifest ataxia. The findings in non-converters show that the available clinical outcome parameters lack sensitivity in the premanifest phase.

References: [1] Jacobi H, Reetz K, du Montcel ST et al.. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol. 2013 Jul;12(7):650-8.

To cite this abstract in AMA style:

H. Jacobi, S. Tezenas Dumontcel, T. Klockgether, O. The-Risca-Investigators. Evolution of ataxia in risk persons for spinocerebellar ataxia (SCA) [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/evolution-of-ataxia-in-risk-persons-for-spinocerebellar-ataxia-sca/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/evolution-of-ataxia-in-risk-persons-for-spinocerebellar-ataxia-sca/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley